Cytomegalovirus Retinitis After Fluocinolone Acetonide (Retisert™) Implant

Rafael L. Ufret-Vincenty; Rishi P. Singh; Careen Y. Lowder; Peter K. Kaiser

doi:10.1016/j.ajo.2006.09.020

Cytomegalovirus Retinitis After Fluocinolone Acetonide (Retisert™) Implant

Rafael L. Ufret-Vincenty, Rishi P. Singh, Careen Y. Lowder, Peter K. Kaiser

Research output: Contribution to journal › Article › peer-review

64 Scopus citations

Abstract

Purpose: To report a case of cytomegalovirus (CMV) retinitis after placement of a fluocinolone acetonide (Retisert™) implant. Design: Interventional case report. Methods: Retrospective chart review. Results: A 65-year-old man with a history of Adamantiades-Behcet disease and bilateral recurrent uveitis that was unresponsive to systemic corticosteroid-sparing immunosuppressive therapy developed clinical evidence of CMV retinitis after receiving his second intravitreal Retisert™ implant in the left eye, while on no systemic immunosuppression. He did not develop CMV retinitis in the right eye despite multiple intraocular and periocular steroid injections. The patient responded well to intravitreal foscarnet followed by placement of an intravitreal ganciclovir implant. Conclusions: Ophthalmologists should be aware of the potential risk for development of CMV retinitis after local ocular immunosuppressive therapy.

Original language	English (US)
Pages (from-to)	334-335
Number of pages	2
Journal	American journal of ophthalmology
Volume	143
Issue number	2
DOIs	https://doi.org/10.1016/j.ajo.2006.09.020
State	Published - Feb 2007

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/j.ajo.2006.09.020

Cite this

@article{ceb2692b242043e48928f470cee71412,

title = "Cytomegalovirus Retinitis After Fluocinolone Acetonide (Retisert{\texttrademark}) Implant",

abstract = "Purpose: To report a case of cytomegalovirus (CMV) retinitis after placement of a fluocinolone acetonide (Retisert{\texttrademark}) implant. Design: Interventional case report. Methods: Retrospective chart review. Results: A 65-year-old man with a history of Adamantiades-Behcet disease and bilateral recurrent uveitis that was unresponsive to systemic corticosteroid-sparing immunosuppressive therapy developed clinical evidence of CMV retinitis after receiving his second intravitreal Retisert{\texttrademark} implant in the left eye, while on no systemic immunosuppression. He did not develop CMV retinitis in the right eye despite multiple intraocular and periocular steroid injections. The patient responded well to intravitreal foscarnet followed by placement of an intravitreal ganciclovir implant. Conclusions: Ophthalmologists should be aware of the potential risk for development of CMV retinitis after local ocular immunosuppressive therapy.",

author = "Ufret-Vincenty, {Rafael L.} and Singh, {Rishi P.} and Lowder, {Careen Y.} and Kaiser, {Peter K.}",

year = "2007",

month = feb,

doi = "10.1016/j.ajo.2006.09.020",

language = "English (US)",

volume = "143",

pages = "334--335",

journal = "American journal of ophthalmology",

issn = "0002-9394",

publisher = "Elsevier USA",

number = "2",

}

TY - JOUR

T1 - Cytomegalovirus Retinitis After Fluocinolone Acetonide (Retisert™) Implant

AU - Ufret-Vincenty, Rafael L.

AU - Singh, Rishi P.

AU - Lowder, Careen Y.

AU - Kaiser, Peter K.

PY - 2007/2

Y1 - 2007/2

N2 - Purpose: To report a case of cytomegalovirus (CMV) retinitis after placement of a fluocinolone acetonide (Retisert™) implant. Design: Interventional case report. Methods: Retrospective chart review. Results: A 65-year-old man with a history of Adamantiades-Behcet disease and bilateral recurrent uveitis that was unresponsive to systemic corticosteroid-sparing immunosuppressive therapy developed clinical evidence of CMV retinitis after receiving his second intravitreal Retisert™ implant in the left eye, while on no systemic immunosuppression. He did not develop CMV retinitis in the right eye despite multiple intraocular and periocular steroid injections. The patient responded well to intravitreal foscarnet followed by placement of an intravitreal ganciclovir implant. Conclusions: Ophthalmologists should be aware of the potential risk for development of CMV retinitis after local ocular immunosuppressive therapy.

AB - Purpose: To report a case of cytomegalovirus (CMV) retinitis after placement of a fluocinolone acetonide (Retisert™) implant. Design: Interventional case report. Methods: Retrospective chart review. Results: A 65-year-old man with a history of Adamantiades-Behcet disease and bilateral recurrent uveitis that was unresponsive to systemic corticosteroid-sparing immunosuppressive therapy developed clinical evidence of CMV retinitis after receiving his second intravitreal Retisert™ implant in the left eye, while on no systemic immunosuppression. He did not develop CMV retinitis in the right eye despite multiple intraocular and periocular steroid injections. The patient responded well to intravitreal foscarnet followed by placement of an intravitreal ganciclovir implant. Conclusions: Ophthalmologists should be aware of the potential risk for development of CMV retinitis after local ocular immunosuppressive therapy.

UR - http://www.scopus.com/inward/record.url?scp=33846376130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846376130&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2006.09.020

DO - 10.1016/j.ajo.2006.09.020

M3 - Article

C2 - 17258523

AN - SCOPUS:33846376130

SN - 0002-9394

VL - 143

SP - 334

EP - 335

JO - American journal of ophthalmology

JF - American journal of ophthalmology

IS - 2

ER -

Cytomegalovirus Retinitis After Fluocinolone Acetonide (Retisert™) Implant

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this